½ÃÀ庸°í¼­
»óǰÄÚµå
1762319

¼¼°èÀÇ ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå, ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, ±â¼úº°, Áö¿ªº°, ¿¹Ãø(2025-2034³â)

Molecular Diagnostics For Sexually Transmitted Diseases Market Size, Share, Trends, & Industry Analysis Report By Product (Instruments & Services, Consumables, and Software), By Application, By Technology, By Region - Market Forecast, 2025-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 123 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼ºº´ ºÐÀÚÁø´Ü ¼¼°è ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 78¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¼ºº´(STD) ºÐÀÚÁø´ÜÀº ¼ºº´À» ÀÏÀ¸Å°´Â ¹Ì»ý¹°ÀÇ DNA, RNA µî À¯Àü¹°ÁúÀ» È®ÀÎÇÏ´Â °íµµÀÇ ½ÇÇè ±â¼úÀ» Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. Ç×ü³ª ¹è¾ç¾×À» °Ë»çÇÏ´Â ±âÁ¸ ¹æ½Ä°ú ´Þ¸® ºÐÀÚ°Ë»ç´Â º´¿øÃ¼ ÀÚü¸¦ Á÷Á¢ È®ÀÎÇÕ´Ï´Ù. À̸¦ ÅëÇØ Á¤È®ÇÏ°í ¹Î°¨ÇÑ °ËÃâÀÌ °¡´ÉÇØÁ® °¨¿° Ãʱ⠴ܰ質 Áõ»óÀÌ ¾ÆÁ÷ ³ªÅ¸³ªÁö ¾ÊÀº ´Ü°è¿¡¼­µµ Áø´ÜÀÌ °¡´ÉÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù.

¼ºº´ ºÐÀÚÁø´Ü ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î ¼ºº´ À¯º´·ü Áõ°¡·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, °øÁߺ¸°Ç ¹®Á¦¸¦ °ü¸®Çϱâ À§ÇØ º¸´Ù È¿°úÀûÀÌ°í ½Å¼ÓÇÑ Áø´Ü ¼Ö·ç¼ÇÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ º´¿øÃ¼¸¦ µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º ºÐ¼®¹ý °³¹ß µî ºÐÀÚ °Ë»çÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀ¸·Î °Ë»ç È¿À²¼º°ú Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¼ºº´ÀÇ Á¶±â ¹× Á¤È®ÇÑ Áø´ÜÀÇ Á߿伺¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ÀϹÝÀÎÀÇ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ÀÌ·¯ÇÑ Ã·´Ü Áø´Ü¹ýÀÇ Ã¤Åà Ȯ´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Á¦Ç°º°·Î´Â ½Ã¾à ¹× ŰƮ¸¦ Æ÷ÇÔÇÑ ¼Ò¸ðǰ ºÐ¾ß°¡ ¸ðµç ºÐÀÚ ¼ºº´ °Ë»ç¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â CT/NG °Ë»ç ºÐ¾ß°¡ 2024³â¿¡ Áö¹èÀûÀ̾ú½À´Ï´Ù.

±â¼ú Ãø¸é¿¡¼­´Â Áß¾Ó ÁýÁᫎ ½ÇÇè½ÇÀÇ È®¸³µÈ ÀÎÇÁ¶ó¿¡ ÈûÀÔ¾î ½ÇÇè½Ç °Ë»ç ºÎ¹®ÀÌ 2024³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Abbott Laboratories, F. Hoffmann-La Roche AG(Roche Diagnostics), bioMerieux SA, QIAGEN N.V., Hologic Inc. Company£¨BD£©,Siemens Healthineers AG,DiaSorin S.p.A.,Thermo Fisher Scientific Inc. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå ºÐ¼®

  • ½ÃÀå ÇöȲ
  • ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PESTEL ºÐ¼®
  • ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå ¿ëµµ µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå : Á¦Ç°º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ±â±â ¹× ¼­ºñ½º
  • ¼Ò¸ðǰ
  • ¼ÒÇÁÆ®¿þ¾î

Á¦6Àå ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå : ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • CT/NG °Ë»ç
  • ¸Åµ¶ °Ë»ç
  • ÀÓÁú °Ë»ç
  • HSV °Ë»ç
  • HPV °Ë»ç
  • HIV °Ë»ç
  • Æ®¸®Äڸ𳪽º
  • ¿ì·¹¾Æ ÇöóÁ+ ¸¶ÀÌÄÚÇöóÁ
  • ±âŸ

Á¦7Àå ¼ºº´ ºÐÀÚÁø´Ü ¼¼°è ½ÃÀå : ±â¼úº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ÀÓ»ó °Ë»ç
  • PoC Å×½ºÆ®

Á¦8Àå ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼ºº´ ºÐÀÚÁø´Ü ½ÃÀå Æò°¡ : Áö¿ªº°, 2020-2034³â
  • ºÏ¹Ì
    • ºÏ¹Ì : Á¦Ç°º°, 2020-2034³â
    • ºÏ¹Ì : ¿ëµµº°, 2020-2034³â
    • ºÏ¹Ì : ±â¼úº°, 2020-2034³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ : Á¦Ç°º°, 2020-2034³â
    • À¯·´ : ¿ëµµº°, 2020-2034³â
    • À¯·´ : ±â¼úº°, 2020-2034³â
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Á¦Ç°º°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¿ëµµº°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±â¼úº°, 2020-2034³â
    • Áß±¹
    • Àεµ
    • ¸»·¹À̽þÆ
    • ÀϺ»
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Á¦Ç°º°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¿ëµµº°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±â¼úº°, 2020-2034³â
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : Á¦Ç°º°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¿ëµµº°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±â¼úº°, 2020-2034³â
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • È®´ë¿Í Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦10Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Becton, Dickinson and Company(BD)
  • bioMerieux SA
  • DiaSorin S.p. A.
  • F. Hoffmann-La Roche AG(Roche Diagnostics)
  • Hologic Inc.
  • QIAGEN N.V.
  • QuidelOrtho Corporation
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
LSH 25.07.10

The global molecular diagnostics for sexually transmitted diseases market size is expected to reach USD 7.85 billion by 2034, according to a new study by Polaris Market Research. The report "Molecular Diagnostics for Sexually Transmitted Diseases Market Size, Share, Trends, & Industry Analysis Report By Product (Instruments & Services, Consumables, and Software), By Application, By Technology, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Molecular diagnostics for sexually transmitted diseases (STDs) involves advanced laboratory techniques that pinpoint the genetic material, such as DNA or RNA, of the microorganisms causing these infections. Unlike older methods that might look for antibodies or grown cultures, molecular tests directly identify the pathogen itself. This allows for highly accurate and sensitive detection, often enabling diagnosis even in the early stages of an infection or when symptoms are not yet present, which is crucial for timely treatment and preventing further spread.

The market for molecular diagnostics for STDs is experiencing significant growth due to the rising global incidence of STDs, which necessitates more effective and rapid diagnostic solutions to manage public health challenges. Additionally, ongoing technological advancements in molecular testing, including the development of multiplex assays that can detect multiple pathogens simultaneously, are enhancing testing efficiency and accessibility. The increasing awareness among healthcare professionals and the general public about the importance of early and accurate STD diagnosis also contributes to the expanding adoption of these advanced diagnostic methods.

Molecular Diagnostics for Sexually Transmitted Diseases Market Report Highlights:

By product, the consumables segment, encompassing reagents and kits, holds the largest share due to its essential role in every molecular STD test.

Based on application, the CT/NG testing segment dominated in 2024 as these are among the most prevalent STDs worldwide.

In terms of technology, the laboratory testing segment held the largest share in 2024, supported by the established infrastructure of centralized labs.

By region, North America dominated the molecular diagnostics for sexually transmitted diseases market revenue share in 2024. Asia Pacific is projected to witness the fastest growth during the forecast period.

A few key players in the market include Abbott Laboratories; F. Hoffmann-La Roche AG (Roche Diagnostics); bioMerieux SA; QIAGEN N.V.; Hologic Inc.; Becton, Dickinson and Company (BD); Siemens Healthineers AG; DiaSorin S.p.A.; Thermo Fisher Scientific Inc.; QuidelOrtho Corporation; and Seegene Inc.

Polaris Market Research has segmented the molecular diagnostics for sexually transmitted diseases market report on the basis of product, application, technology, and region:

By Product Outlook (Revenue - USD Billion, 2020-2034)

Instruments & Services

Consumables

Software

By Application Outlook (Revenue - USD Billion, 2020-2034)

CT/NG Testing

Syphilis Testing

Gonorrhea Testing

HSV Testing

HPV Testing

HIV Testing

Trichomonas

Ureaplasma + Mycoplasma

Others

By Technology Outlook (Revenue - USD Billion, 2020-2034)

Laboratory Testing

Commercial/Private Labs

Public Health Labs

PoC testing

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Insights

  • 4.1. Molecular Diagnostics For Sexually Transmitted Diseases Market - Market Snapshot
  • 4.2. Molecular Diagnostics For Sexually Transmitted Diseases Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Incidence of Sexually Transmitted Diseases
      • 4.2.1.2. Technological Advancements in Diagnostic Tools
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Diagnostic Tests and Equipment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Molecular Diagnostics For Sexually Transmitted Diseases Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
  • 5.3. Instruments & Services
    • 5.3.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Instruments & Services, by Region, 2020-2034 (USD Billion)
  • 5.4. Consumables
    • 5.4.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Consumables, by Region, 2020-2034 (USD Billion)
  • 5.5. Software
    • 5.5.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Software, by Region, 2020-2034 (USD Billion)

6. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
  • 6.3. CT/NG testing
    • 6.3.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by CT/NG testing, by Region, 2020-2034 (USD Billion)
  • 6.4. Syphilis testing
    • 6.4.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Syphilis testing, by Region, 2020-2034 (USD Billion)
  • 6.5. Gonorrhea testing
    • 6.5.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Gonorrhea testing, by Region, 2020-2034 (USD Billion)
  • 6.6. HSV testing
    • 6.6.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by HSV testing, by Region, 2020-2034 (USD Billion)
  • 6.7. HPV testing
    • 6.7.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by HPV testing, by Region, 2020-2034 (USD Billion)
  • 6.8. HIV testing
    • 6.8.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by HIV testing, by Region, 2020-2034 (USD Billion)
  • 6.9. Trichomonas
    • 6.9.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Trichomonas, by Region, 2020-2034 (USD Billion)
  • 6.10. Ureaplasma + Mycoplasma
    • 6.10.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Ureaplasma + Mycoplasma, by Region, 2020-2034 (USD Billion)
  • 6.11. Others
    • 6.11.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
  • 7.3. Laboratory Testing
    • 7.3.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Laboratory Testing, by Region, 2020-2034 (USD Billion)
    • 7.3.2. Commercial/Private Labs
    • 7.3.3. Public Health Labs
  • 7.4. PoC testing
    • 7.4.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by PoC testing, by Region, 2020-2034 (USD Billion)

8. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Molecular Diagnostics For Sexually Transmitted Diseases Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Molecular Diagnostics For Sexually Transmitted Diseases Market - North America
    • 8.3.1. North America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
    • 8.3.2. North America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
    • 8.3.3. North America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.3.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - U.S.
      • 8.3.4.1. U.S.: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.3.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - Canada
      • 8.3.5.1. Canada: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
  • 8.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Europe
    • 8.4.1. Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - UK
      • 8.4.4.1. UK: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - France
      • 8.4.5.1. France: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Germany
      • 8.4.6.1. Germany: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Italy
      • 8.4.7.1. Italy: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.8. Molecular Diagnostics For Sexually Transmitted Diseases Market - Spain
      • 8.4.8.1. Spain: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.9. Molecular Diagnostics For Sexually Transmitted Diseases Market - Netherlands
      • 8.4.9.1. Netherlands: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.10. Molecular Diagnostics For Sexually Transmitted Diseases Market - Russia
      • 8.4.10.1. Russia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.4.11. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
  • 8.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - Asia Pacific
    • 8.5.1. Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - China
      • 8.5.4.1. China: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - India
      • 8.5.5.1. India: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Malaysia
      • 8.5.6.1. Malaysia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Japan
      • 8.5.7.1. Japan: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.8. Molecular Diagnostics For Sexually Transmitted Diseases Market - Indonesia
      • 8.5.8.1. Indonesia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.9. Molecular Diagnostics For Sexually Transmitted Diseases Market - South Korea
      • 8.5.9.1. South Korea: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.10. Molecular Diagnostics For Sexually Transmitted Diseases Market - Australia
      • 8.5.10.1. Australia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.5.11. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
  • 8.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.6.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.6.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - UAE
      • 8.6.5.1. UAE: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.6.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Israel
      • 8.6.6.1. Israel: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.6.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - South Africa
      • 8.6.7.1. South Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.6.8. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
  • 8.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Latin America
    • 8.7.1. Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.7.4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Mexico
      • 8.7.4.1. Mexico: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.7.5. Molecular Diagnostics For Sexually Transmitted Diseases Market - Brazil
      • 8.7.5.1. Brazil: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.7.6. Molecular Diagnostics For Sexually Transmitted Diseases Market - Argentina
      • 8.7.6.1. Argentina: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)
    • 8.7.7. Molecular Diagnostics For Sexually Transmitted Diseases Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Product, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Application, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Molecular Diagnostics For Sexually Transmitted Diseases Market, by Technology, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Becton, Dickinson and Company (BD)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. bioMerieux SA
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. DiaSorin S.p. A.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. F. Hoffmann-La Roche AG (Roche Diagnostics)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Hologic Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. QIAGEN N.V.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. QuidelOrtho Corporation
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Seegene Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Siemens Healthineers AG
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Thermo Fisher Scientific Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦